---
title: "Cancer vaccines and neoantigen strategies in the immunotherapy era"
id: "nature-reviews-clinical-oncology-1-cancer-vaccines-in-the-era-of-immunotherapy-from-antigen-delivery-to-immune"
canonical_url: "https://medichelpline.com/clinical-feed/nature-reviews-clinical-oncology-1-cancer-vaccines-in-the-era-of-immunotherapy-from-antigen-delivery-to-immune"
content_type: "clinical_feed_article"
specialty: "Oncology"
source_name: "Nature Reviews Clinical Oncology"
source_url: "https://www.nature.com/articles/s41571-026-01224-0"
published_at: "2026-11-17T12:00:00.000Z"
evidence_level: "Journal Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Cancer vaccines and neoantigen strategies in the immunotherapy era
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/nature-reviews-clinical-oncology-1-cancer-vaccines-in-the-era-of-immunotherapy-from-antigen-delivery-to-immune
- **Specialty:** [Oncology](https://medichelpline.com/clinical-feed/oncology.md)
- **Primary Source:** Nature Reviews Clinical Oncology
- **Source URL:** [Original Journal Publication](https://www.nature.com/articles/s41571-026-01224-0)
- **Published At:** 2026-11-17T12:00:00.000Z
- **Evidence Rating:** Journal Feed
## Executive GIST (TL;DR)
- Therapeutic **cancer vaccines** reliably induce tumour-specific immune responses, but translating immunogenicity into durable tumour control remains a central clinical problem. - Investigators reported multiple biological bottlenecks: antigen selection and presentation; T cell priming, trafficking and infiltration; functional exhaustion; and tumour immune evasion. - Early vaccines targeted shared self-antigens and faced tolerance and weak priming; personalized **neoantigen** vaccines target tumour-specific mutations not subject to central tolerance. - The cohort of neoantigen vaccine trials showed robust induction of neoantigen-specific CD4+ and CD8+ T cell responses; immunogenicity is less problematic than downstream barriers. - Vaccine-induced T cell clones can persist for years, adopt memory phenotypes, re-expand after boosting and broaden through epitope spreading, indicating durable reshaping of the antitumour repertoire. - Vaccine platforms should be viewed as modulators of antigen presentation and innate activation—peptide, **mRNA–LNP**, viral-vector and dendritic cell approaches balance epitope precision against intrinsic adjuvanticity and scalability. - Clinical benefit is strongly dependent on disease setting. Evidence for benefit is strongest in minimal residual disease and adjuvant settings, with phase III randomized trial evidence reported in resected melanoma. - Specific trial signals in the adjuvant setting include autogene cevumeran combined with atezolizumab and mFOLFIRINOX in resected pancreatic ductal adenocarcinoma (associated with prolonged recurrence-free survival in the report) and intismeran autogene with pembrolizumab in resected stage IIIB–IV melanoma. - In advanced-stage disease, vaccine immunogenicity can remain robust but clinical benefit has been limited in multiple studies. - Priorities flagged by the authors include validated immune correlates of benefit, rational combination and sequencing with checkpoint inhibitors, exploitation of neoadjuvant/perioperative windows, confirmatory randomized trials and exploration of cancer interception in high-risk individuals.
## Clinical Analysis & Structured Key Points
## Your privacy, your choice We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media, as well as to allow video information to be shared for both marketing, analytics and editorial purposes. By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection. See our [privacy policy](https://www.nature.com/info/privacy) for more information on the use of your personal data. Manage preferences for further information and to change your choices. Accept all cookies Reject optional cookies [Skip to main content](https://www.nature.com/articles/s41571-026-01224-0#content) Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript. Advertisement [ ![Nature Reviews Clinical Oncology](https://media.springernature.com/full/nature-cms/uploads/product/nrclinonc/header-6cacb5c22900eb4634682a8eae5b788c.svg) ](https://www.nature.com/nrclinonc) * [ View all journals ](https://www.nature.com/siteindex) * [ Saved research ](https://www.nature.com/saved-research) * [ Search ](javascript:;) ## Search Search articles by subject, keyword or author Show results from All journals This journal Search [ Advanced search ](https://www.nature.com/search/advanced) ### Quick links * [Explore articles by subject](https://www.nature.com/subjects) * [Find a job](https://www.nature.com/naturecareers) * [Guide to authors](https://www.nature.com/authors/index.html) * [Editorial policies](https://www.nature.com/authors/editorial_policies/) * [Log in](https://idp.nature.com/auth/personal/springernature?redirect_uri=https://www.nature.com/articles/s41571-026-01224-0) * [ Content Explore content ](javascript:;) ## Explore content * [ Research articles ](https://www.nature.com/nrclinonc/research-articles) * [ Reviews & Analysis ](https://www.nature.com/nrclinonc/reviews-and-analysis) * [ News & Comment ](https://www.nature.com/nrclinonc/news-and-comment) * [ Current issue ](https://www.nature.com/nrclinonc/current-issue) * [ Collections ](https://www.nature.com/nrclinonc/collections) * [Follow us on Facebook ](https://www.facebook.com/NatureReviews) * [Follow us on X ](https://twitter.com/NatRevClinOncol) * [ Subscribe ](https://www.nature.com/nrclinonc/subscribe) * [Sign up for alerts ](https://journal-alerts.springernature.com/subscribe?journal_id=41571) * [ RSS feed ](https://www.nature.com/nrclinonc.rss) * [ About the journal ](javascript:;) ## About the journal * [ Aims & Scope ](https://www.nature.com/nrclinonc/aims) * [ Journal Information ](https://www.nature.com/nrclinonc/journal-information) * [ Editors ](https://www.nature.com/nrclinonc/editors) * [ Editorial policies ](https://www.nature.com/nrclinonc/editorial-policies) * [ Reviews Cross-Journal Editorial Team ](https://www.nature.com/nrclinonc/reviews-cross-journal-editorial-team) * [ Journal Credits ](https://www.nature.com/nrclinonc/journal-credits) * [ Editorial input and checks ](https://www.nature.com/nrclinonc/editorial-input-and-checks) * [ Editorial Values Statement ](https://www.nature.com/nrclinonc/editorial-values-statement) * [ Journal Metrics ](https://www.nature.com/nrclinonc/journal-impact) * [ Publishing model ](https://www.nature.com/nrclinonc/publishing-model) * [ Conferences ](https://www.nature.com/nrclinonc/conferences) * [ Web Feeds ](https://www.nature.com/nrclinonc/web-feeds) * [ Contact ](https://www.nature.com/nrclinonc/contact) * [ Publish with us ](javascript:;) ## Publish with us * [ For Authors ](https://www.nature.com/nrclinonc/for-authors) * [ For Referees ](https://www.nature.com/nrclinonc/for-referees) * [Submit manuscript ](https://mts-nrclinonc.nature.com/cgi-bin/main.plex) * [ Subscribe ](https://www.nature.com/nrclinonc/subscribe) * [ Sign up for alerts ](https://journal-alerts.springernature.com/subscribe?journal_id=41571) * [ RSS feed ](https://www.nature.com/nrclinonc.rss) 1. [nature](https://www.nature.com/) 2. [nature reviews clinical oncology](https://www.nature.com/nrclinonc) 3. [review articles](https://www.nature.com/nrclinonc/articles?type=review-article) 4. article * Review Article * Published: 17 November 2026 # Cancer vaccines in the era of immunotherapy: from antigen delivery to immune ecosystem engineering * [Adrien P. Mouren](https://www.nature.com/articles/s41571-026-01224-0#auth-Adrien_P_-Mouren-Aff1-Aff2-Aff3) [ORCID: orcid.org/0009-0004-1649-5615](https://orcid.org/0009-0004-1649-5615)[1](https://www.nature.com/articles/s41571-026-01224-0#Aff1),[2](https://www.nature.com/articles/s41571-026-01224-0#Aff2),[3](https://www.nature.com/articles/s41571-026-01224-0#Aff3) & * [Patrick A. Ott](https://www.nature.com/articles/s41571-026-01224-0#auth-Patrick_A_-Ott-Aff1-Aff4-Aff5) [ORCID: orcid.org/0000-0002-4253-943X](https://orcid.org/0000-0002-4253-943X)[1](https://www.nature.com/articles/s41571-026-01224-0#Aff1),[4](https://www.nature.com/articles/s41571-026-01224-0#Aff4),[5](https://www.nature.com/articles/s41571-026-01224-0#Aff5) [_Nature Reviews Clinical Oncology_](https://www.nature.com/nrclinonc) (2026) [Cite this article](https://www.nature.com/articles/s41571-026-01224-0#citeas) Save article [ View saved research ](https://www.nature.com/saved-research) ## Abstract Therapeutic cancer vaccines reliably induce tumour-specific immune responses, although translating this immunogenicity into durable tumour control remains a major challenge. This disconnect is probably the result of a series of biological bottlenecks, from antigen selection and presentation to T cell priming, tumour infiltration and resistance to immune suppression. Advances in neoantigen identification, vaccine technologies, immune profiling and computational biology have renewed and re-energized the field. Emerging evidence from clinical trials testing neoantigen-directed vaccines indicates that therapeutic vaccination can improve clinical outcomes particularly when applied in earlier disease settings and integrated within broader immunotherapeutic strategies. In this Review, we examine the mechanisms limiting vaccine efficacy, discuss how they are informing the design of next-generation vaccines, and explore the biomarkers and therapeutic strategies that might enable vaccination to achieve more consistent clinical benefit. ## Key points * Early-generation therapeutic cancer vaccines targeted shared self-antigens and were constrained by immunological tolerance and suboptimal T cell priming, eliciting measurable immune responses but rarely tumour regression. A new generation of personalized neoantigen vaccines instead target tumour-specific mutations that are not subject to central tolerance. * Personalized neoantigen vaccines now reliably induce neoantigen-specific CD4+ T cell and CD8+ T cell responses. Immunogenicity is no longer the principal obstacle; clinical benefit is limited by sequential bottlenecks spanning antigen presentation, T cell priming, trafficking and exhaustion, and tumour immune evasion. * Vaccine-induced T cell clones can persist for years, acquire memory phenotypes, re-expand after boosting and broaden through epitope spreading, indicating that a single vaccination course can durably reshape the antitumour T cell repertoire. * Vaccine platforms are better understood as modulators of antigen presentation and innate immune activation than as merely antigen delivery systems; peptide, mRNA, viral vector and dendritic cell approaches trade epitope-level precision against intrinsic adjuvanticity and scalability. * Clinical benefit from cancer vaccines depends strongly on the disease setting. The strongest evidence comes from minimal residual disease and adjuvant settings after complete tumour resection, including phase III randomized trial evidence in patients with resected melanoma, whereas advanced-stage disease remains substantially more challenging. * Priorities for the field include validated immune correlates of clinical benefit, rational combination and sequencing with immune checkpoint inhibitors, exploitation of the neoadjuvant and perioperative window, confirmatory randomized trials and extension of vaccination to cancer interception in individuals at high risk. This is a preview of subscription content, [access via your institution](https://wayf.springernature.com?redirect_uri=https%3A%2F%2Fwww.nature.com%2Farticles%2Fs41571-026-01224-0) ## Access options [ Access through your institution ](https://wayf.springernature.com?redirect_uri=https%3A%2F%2Fwww.nature.com%2Farticles%2Fs41571-026-01224-0) Access Nature and 54 other Nature Portfolio journals Get Nature+, our best-value online-access subscription 32.70 € / 30 days cancel any time [Learn more](https://shop.nature.com/products/plus/?region=ROW) Subscribe to this journal Receive 12 print issues and online access 176.64 € per year only 14.72 € per issue [Learn more](https://www.nature.com/nrclinonc/subscribe) Buy this article * Purchase on SpringerLink * Instant access to the full article PDF. 39,95 € Prices may be subject to local taxes which are calculated during checkout ### Additional access options: * [Log in](https://idp.nature.com/auth/personal/springernature?client_id=grover&redirect_uri=https%3A%2F%2Fwww.nature.com%2Farticles%2Fs41571-026-01224-0) * [Learn about institutional subscriptions](https://www.springernature.com/gp/librarians/licensing/license-options) * [Read our FAQs](https://support.nature.com/en/support/home) * [Contact customer support](https://www.springernature.com/gp/contact) **Fig. 1: Addressing bottlenecks to effective antitumour immunity through vaccination.** ![This image explains five key challenges in cancer vaccine effectiveness and corresponding strategies to overcome them. \(1\) Antigen presentation: insufficient dendritic cell activation can limit vaccine-induced immune priming. Delivering antigen together with immune adjuvants that activate STING and toll-like receptors enhances dendritic cell activation. \(2\) T cell priming and repertoire breadth: some vaccine strategies may induce a narrow, low-quality CD8-positive T cell response. Including many clonal neoantigens that present both MHC class I and II epitopes broadens the T cell response, engaging both CD8-positive and CD4-positive T cells. \(3\) Trafficking and infiltration: T cells are often excluded from tumours by the tumour microenvironment. Combining vaccines with tumour microenvironment remodelling therapies, such as anti-angiogenic agents and chemokine modulators, promotes immune cell infiltration into tumours. \(4\) Function and exhaustion: chronic antigen exposure causes T cell exhaustion marked by PD-1 expression. Combining vaccines with immune checkpoint blockade antibodies \(anti-PD-1\), co-stimulatory agonists \(anti-CD40\) and cytokines \(IL-2, IL-2 receptor agonists\) can help restore T cell function. \(5\) Tumour immune evasion: tumours evade immunity by losing antigens or downregulating MHC class I expression. Broadening antigen coverage and promoting epitope spreading may help sustain immunological pressure and support durable tumour control. Failure to address these challenges results in ineffective antitumour immune responses.](https://media.springernature.com/m312/springer-static/image/art%3A10.1038%2Fs41571-026-01224-0/MediaObjects/41571_2026_1224_Fig1_HTML.png) **Fig. 2: Vaccine platforms differ in their control over antigen presentation and APC activation.** ![This image compares four vaccine types—peptide, mRNA–LNP, viral-vector and dendritic cell-based—focusing on how epitopes are defined or presented and the control over epitope presentation and antigen-presenting cell activation. Each vaccine type is illustrated with a dendritic cell displaying MHC class I and II molecules, with question marks indicating uncertainty in epitope presentation for mRNA–LNP and viral-vector vaccines. Peptide vaccines define epitopes in vitro at the protein level, presenting precise and interrogable epitopes via MHC class I and II molecules on dendritic cells, with high control over presented epitopes but low capacity to promote antigen-presenting cell activation, relying on exogenous adjuvants. mRNA-LNP vaccines deliver mRNA encapsulated in lipid nanoparticles, with epitope presentation and translation determined by cellular processes including ribosomes and proteasomes. They have lower control over presented epitopes but moderate capacity to promote antigen-presenting cell activation, offering multiplexable and self-adjuvanting properties, although presented epitopes are less predictable. Viral-vector vaccines use viruses to deliver antigen expression, with epitope presentation determined by cellular processes. They show moderate control over presented epitopes and high capacity to promote antigen-presenting cell activation, characterized by strong antigen expression and innate activation, but face anti-vector immunity and safety constraints. Dendritic cell-based vaccines involve ex vivo antigen loading and antigen-presenting cell activation, allowing direct control of antigen-presenting cell phenotype and antigen loading. The degree of control over presented epitopes depends on the antigen-loading strategy.](https://media.springernature.com/m312/springer-static/image/art%3A10.1038%2Fs41571-026-01224-0/MediaObjects/41571_2026_1224_Fig2_HTML.png) **Fig. 3: Disease setting as a determinant of vaccine efficacy.** ![The image compares clinical benefit and immunological barriers between minimal residual disease or adjuvant settings and advanced-stage or metastatic disease in cancer treatment. It shows that the probability of clinical benefit and the window for durable tumour control decrease as disease progresses from minimal residual disease to an advanced stage. Vaccine immunogenicity can remain robust across these settings despite differences in clinical benefit. Immunological barriers such as tumour burden, tumour microenvironment and systemic immunosuppression, T cell exhaustion, and antigen loss with immune evasion accumulate and increase from early to advanced disease stages. Examples of clinical trials are provided: for resected pancreatic ductal adenocarcinoma, autogene cevumeran combined with atezolizumab and mFOLFIRINOX shows association with prolonged recurrence-free survival and emerging overall survival signals; for resected stage IIIB-IV melanoma, intismeran autogene combined with pembrolizumab shows randomized trial evidence of clinical benefit. In contrast, studies of autogene cevumeran in advanced solid tumours and personalized neoantigen vaccination in advanced melanoma have not demonstrated clear clinical benefit in the settings illustrated.](https://media.springernature.com/m312/springer-static/image/art%3A10.1038%2Fs41571-026-01224-0/MediaObjects/41571_2026_1224_Fig3_HTML.png) **Fig. 4: The neoadjuvant and perioperative window for personalized vaccination.** ![The image shows a timeline that outlines a treatment sequence starting with neoadjuvant therapy when the tumour and its antigens are present, followed by tumour resection, and then consolidation therapy after pre-operative immunomodulating therapy. During neoadjuvant therapy, the NECVAX-NEO1 vaccine is given before surgery with anti-PD-1 antibody and chemotherapy, continuing anti-PD-1 antibody after surgery with optional vaccine continuation, aiming to prime antitumour immune responses before surgery. The surgery phase is described as a translational window where the resected specimen is assessed for immune infiltration, antigen presentation and T cell functionality to link mechanism to outcome. In consolidation, minimal residual disease and remodelled tumour microenvironment are present. The NeoVax plus CDX-301 treatment for melanoma involves anti-PD-1 antibody before resection without vaccine, followed by vaccine administration after resection with continued anti-PD-1 antibody, potentially recruiting new T cell specificities against disease that escaped pre-operative therapy.](https://media.springernature.com/m312/springer-static/image/art%3A10.1038%2Fs41571-026-01224-0/MediaObjects/41571_2026_1224_Fig4_HTML.png) ### Explore related subjects Discover the latest articles and news in related subjects. * [Drug development](https://www.nature.com/subjects/drug-development) * [Immunotherapy](https://www.nature.com/subjects/immunotherapy) * [Tumour immunology](https://www.nature.com/subjects/tumour-immunology) ## References 1. Melero, I. et al. Therapeutic vaccines for cancer: an overview of clinical trials. _Nat. Rev. Clin. Oncol._ **11** , 509–524 (2014). [Article](https://doi.org/10.1038%2Fnrclinonc.2014.111) [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC2cXhtFWiu7zJ) [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=25001465) [ Google Scholar](http://scholar.google.com/scholar_lookup?&title=Therapeutic%20vaccines%20for%20cancer%3A%20an%20overview%20of%20clinical%20trials&journal=Nat.%20Rev.%20Clin.%20Oncol.&doi=10.1038%2Fnrclinonc.2014.111&volume=11&pages=509-524&publication_year=2014&author=Melero%2CI) 2. Saxena, M., van der Burg, S. H., Melief, C. J. M. & Bhardwaj, N. Therapeutic cancer vaccines. _Nat. Rev. Cancer_ **21** , 360–378 (2021). [Article](https://doi.org/10.1038%2Fs41568-021-00346-0) [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3MXps12ltrw%3D) [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=33907315) [ Google Scholar](http://scholar.google.com/scholar_lookup?&title=Therapeutic%20cancer%20vaccines&journal=Nat.%20Rev.%20Cancer&doi=10.1038%2Fs41568-021-00346-0&volume=21&pages=360-378&publication_year=2021&author=Saxena%2CM&author=Burg%2CSH&author=Melief%2CCJM&author=Bhardwaj%2CN) 3. Hollingsworth, R. E. & Jansen, K. Turning the corner on therapeutic cancer vaccines. _NPJ Vaccines_ **4** , 7 (2019). [Article](https://doi.org/10.1038%2Fs41541-019-0103-y) [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=30774998) [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6368616) [ Google Scholar](http://scholar.google.com/scholar_lookup?&title=Turning%20the%20corner%20on%20therapeutic%20cancer%20vaccines&journal=NPJ%20Vaccines&doi=10.1038%2Fs41541-019-0103-y&volume=4&publication_year=2019&author=Hollingsworth%2CRE&author=Jansen%2CK) 4. Melief, C. J. M., van Hall, T., Arens, R., Ossendorp, F. & van der Burg, S. H. Therapeutic cancer vaccines. _J. Clin. Invest._ **125** , 3401–3412 (2015). [Article](https://doi.org/10.1172%2FJCI80009) [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=26214521) [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4588240) [ Google Scholar](http://scholar.google.com/scholar_lookup?&title=Therapeutic%20cancer%20vaccines&journal=J.%20Clin.%20Invest.&doi=10.1172%2FJCI80009&volume=125&pages=3401-3412&publication_year=2015&author=Melief%2CCJM&author=Hall%2CT&author=Arens%2CR&author=Ossendorp%2CF&author=Burg%2CSH) 5. van der Burg, S. H., Arens, R., Ossendorp, F., van Hall, T. & Melief, C. J. M. Vaccines for established cancer: overcoming the challenges posed by immune evasion. _Nat. Rev. Cancer_ **16** , 219–233 (2016). [Article](https://doi.org/10.1038%2Fnrc.2016.16) [PubMed](http://w
## Related Clinical Research

- [Real-world use and outcomes of immune checkpoint inhibitors in the FAIR-ICI multicenter cohort](https://medichelpline.com/clinical-feed/medrxiv-14-comprehensive-real-world-utilization-treatment-trajectories-and-outcomes-of.md)
- [FDA Oncology Approvals 2014–2025: Immunotherapy vs Non‑Immunotherapy Endpoints and Efficacy](https://medichelpline.com/clinical-feed/medrxiv-1-usfda-oncology-drug-approvals-from-2014-2025-comparing-non-immunotherapy-and.md)
- [53L10 T‑cell engager tribody for immunotherapy of multiple solid tumors — Frontiers in Immunology](https://medichelpline.com/clinical-feed/frontiers-in-immunology-11-53l10-t-cell-engager-tribody-for-immunotherapy-of-multiple-solid-tumors.md)
- [Polymer-Based Drug Delivery Targeting the Tumor Microenvironment for Immunotherapy of Triple-Negat](https://medichelpline.com/clinical-feed/frontiers-in-immunology-14-advancements-in-polymer-based-drug-delivery-systems-targeting-the-tumor.md)
- [Immune-pressure redistribution as a framework for resistance to PD-1/PD-L1 blockade](https://medichelpline.com/clinical-feed/pubmed-42763389.md) (DOI: 10.1186/s12943-026-02786-4)

## Navigation
- [← Back to Oncology Feed](https://medichelpline.com/clinical-feed/oncology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.